Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pediatr Clin North Am. 2012 Oct;59(5):1017-37. doi: 10.1016/j.pcl.2012.07.008. Epub 2012 Aug 22.

Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.

Author information

  • 1Section of Cardiology, Children's Mercy Hospital and Clinics, University of Missouri-Kansas City School of Medicine, 2401 Gillham Road, Kansas City, MO 64108, USA. jbwagner@cmh.edu

Abstract

The dose-exposure-response relationship for drugs may differ in pediatric patients compared with adults. Many clinical studies have established drug dose-exposure relationships across the pediatric age spectrum; however, genetic variation was seldom included. This article applies a systematic approach to determine the relative contribution of development and genetic variation on drug disposition and response using HMG-CoA reductase inhibitors as a model. Application of the approach drives the collection of information relevant to understanding the potential contribution of ontogeny and genetic variation to statin dose-exposure-response in children, and identifies important knowledge deficits to be addressed through the design of future studies.

Copyright © 2012 Elsevier Inc. All rights reserved.

PMID:
23036242
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk